Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Stablizing an enzyme by forming a mixture, an adduct or a composition, or formation of an adduct or enzyme conjugate

Subclass of:

435 - Chemistry: molecular biology and microbiology

435183000 - ENZYME (E.G., LIGASES (6. ), ETC.), PROENZYME; COMPOSITIONS THEREOF; PROCESS FOR PREPARING, ACTIVATING, INHIBITING, SEPARATING, OR PURIFYING ENZYMES

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20100055761METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING - The present invention provides methods and compositions for treating various diseases through selective killipg of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.03-04-2010
20110189752COMPLEX - A complex comprising at least one target protein and at least one binding molecule having a binding affinity for said target protein, wherein said molecule having a binding affinity is covalently or non-covalently bound to at least one water-soluble polymer08-04-2011
20110189751METHODS AND COMPOSITIONS COMPRISING HEAT SHOCK PROTEINS - Compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures.08-04-2011
20120184014Photoactive Metal Nitrosyls for Blood Pressure Regulation and Cancer Therapy - Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment.07-19-2012
20120184013Inhibitors of BMX non-receptor tyrosine kinase - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.07-19-2012
20130045522MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES - The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.02-21-2013
20110195478BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME - The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.08-11-2011
20120244598Stabilization of Thermolysin in Aqueous Solution - The present invention deals with the proteolytic enzyme thermolysin which tends to be unstable in aqueous solution. The invention provides methods and compositions to enhance the stability of dissolved thermolysin in aqueous solution. Thermolysin, crude thermolysin or a lyophilisate containing thermolysin and one or more salts, is contacted with an aqueous buffer with a low salt concentration and a first solution is formed. Subsequently, a further salt in solid form is added and dissociated, thereby forming a second solution comprising thermolysin in a stabilized form.09-27-2012
20120244597POLYMER FACTOR VIII MOIETY CONJUGATES - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.09-27-2012
20120244596ANTICALINS - The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.09-27-2012
20130084619MODIFIED CELLULASES WITH ENHANCED THERMOSTABILITY - The present invention relates to modified family-8 cellulases that exhibit enhanced thermostability compared to the corresponding wild-type enzyme, polynucleotides encoding the modified cellulases, compositions comprising same and uses thereof. The variant family-8 cellulases are advantageous for the bioconversion process of cellulosic substrates.04-04-2013
20130084618PHENOLIC BINDING PEPTIDES - The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide conjugate for delivering an agent to a desired target.04-04-2013
20130137157GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA - The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.05-30-2013
20130040362Method for Activation and Conjugation of Biomolecules - The present invention is directed to a method for producing a biomolecule conjugate where the method is integrated into a single unit operation.02-14-2013
20130040361NOVEL ANTIGEN ASSOCIATED WITH THE NEOVASCULATURE OF TUMOUR METASTASES - The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.02-14-2013
20130040360Crystal Structure of the Pro Form of a Matrix Metalloproteinase and an Allosteric Processing Inhibitor - The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues. The present invention also relates to the use of small-molecule allosteric processing inhibitors for the treatment of diseases mediated by inappropriate matrix metalloproteinase (MMP) activity.02-14-2013
20130040363LABELED ENZYME COMPOSITIONS, METHODS AND SYSTEMS - Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are labeled polymerase conjugates including a polymerase linked to one or more labels, wherein the conjugate has polymerase activity. Such conjugates can exhibit enhanced biological activity and/or superior detectability as compared to conventional labeled polymerases. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.02-14-2013
20130029399METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF - A metal-salen complex derivative with an excellent yield and stability is provided and a method for producing such a metal-salen complex derivative is provided. The present invention provides: metal-salen complex derivative obtained by allowing a target component composed of at least one of an enzyme, an antibody, an antigen, a peptide, an amino acid, an oligonucleotide, a protein, a nucleic acid, and a medical molecule to bind to a metal-salen complex via an amide bond or a disulfide bond; a method for producing such a metal-salen complex derivative.01-31-2013
20130052713GH61 GLYCOSIDE HYDROLASE PROTEIN VARIANTS AND COFACTORS THAT ENHANCE GH61 ACTIVITY - The present invention provides various GH61 protein variants comprising various amino acid substitutions. The GH61 protein variants have an improved ability to synergize with cellulase enzymes, thereby increasing the yield of fermentable sugars obtained by saccharification of biomass. In some embodiments, sugars obtained from saccharification are fermented to produce numerous end-products, including but not limited to alcohol.02-28-2013
20110177578APTAMER AGAINST IL-17 AND USE THEREOF - The invention provides an aptamer possessing an inhibitory activity against IL-17, as well as a complex comprising an aptamer possessing a binding activity or inhibitory activity against IL-17 and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like). The invention also provides a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, detection probe, carrier, labeling agent, and the like comprising the aforementioned aptamer or complex, and methods of detecting and purifying IL-17 by using the aforementioned aptamer or complex.07-21-2011
20130059359Protein Nanorings - The invention provides protein nanorings.03-07-2013
20110014675Poly zinc finger proteins with improved linkers - Polynucleotides encoding chimeric proteins, and methods for their production and use are disclosed. The chimeric proteins comprise a flexible linker between two zinc finger DNA-binding domains, wherein the linker contains eight or more amino acids between the second conserved histidine residue of the carboxy-terminal zinc finger of the first domain and the first conserved cysteine residue of the amino-terminal zinc finger of the second domain.01-20-2011
20130059360POLYMER-BASED COMPOSITIONS AND CONJUGATES OF ANTIMICROBIAL AGENTS - Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions.03-07-2013
20110020895METHODS AND COMPOSITIONS FOR DETERMINING ISOMERASE ENZYMATIC ACTIVITY - This disclosure provides crystalline flavonoid or flavanone isomerases, isolated non-native isomerase having the structural coordinates of said crystalline isomerase, and nucleic acids encoding such non-native isomerase. Also disclosed are methods of predicting the activity and/or substrate specificity of a putative isomerase, methods of identifying potential ismerase substrates, and methods of identifying potential isomerase inhibitors.01-27-2011
20080318294Biomolecular Hybrid Material and Process for Preparing Same and Uses for Same - Disclosed is a composition and method for fabricating novel hybrid materials comprised of, e.g., carbon nanotubes (CNTs) and crosslinked enzyme clusters (CECs). In one method, enzyme-CNT hybrids are prepared by precipitation of enzymes which are subsequently crosslinked, yielding crosslinked enzyme clusters (CECs) on the surface of the CNTs. The CEC-enzyme-CNT hybrids exhibit high activity per unit area or mass as well as improved enzyme stability and longevity over hybrid materials known in the art. The CECs in the disclosed materials permit multilayer biocatalytic coatings to be applied to surfaces providing hybrid materials suitable for use in, e.g., biocatalytic applications and devices as described herein.12-25-2008
20130164816Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses - The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.06-27-2013
20130164817POLYPEPTIDES HAVING NUCLEIC ACID BINDING ACTIVITY - Polynucleotides having nucleic acid binding activity are provided. Methods of stabilizing a nucleic acid duplex are provided. Methods of promoting the annealing of complementary nucleic acid strands are provided. Methods of increasing the processivity of a DNA polymerase are provided. Methods of enhancing the activity of a nucleic acid modification enzyme are provided. Fusion proteins are provided. Methods of using fusion proteins are provided. Kits are provided.06-27-2013
20110281322INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.11-17-2011
20110300600METHODS AND COMPOSITIONS FOR DELIVERING POLYNUCLEOTIDES - Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.12-08-2011
20100093056ANTIBODIES THAT BIND DKK-RELATED PROTEINS - Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.04-15-2010
20110300601PROCESSES FOR SYNTHESIZING ALKALINE PHOSPHATASE CONJUGATES - Methods for synthesizing an ALP conjugate are provided. The methods may include activating a carboxyl group of the ALP with a carbodiimide, to generate an active ester; and adding the substance to be conjugated such that a synthetic reaction occurs between the active ester and the substance to be conjugated, to generate an ALP conjugate.12-08-2011
20110300603Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.12-08-2011
20110300602CONJUGATE PREPARATION METHODS AND RELATED KIT - Methods for preparing conjugates including enzyme conjugates and especially alkaline phosphatase (ALP) conjugates, and a kit are provided. The methods include: blocking an amino group on a molecule surface of a first substance to be conjugated containing an amino group and a carboxyl group (for example, an enzyme) with a carboxyl compound; adding a carbodiimide to activate the first substance to be conjugated with the amino group blocked; inactivating or removing the carbodiimide; and adding a second substance containing an amino group (for example, a substance to be labeled). Conjugates (for example, enzyme conjugates) are obtained.12-08-2011
20110143416STABILIZATION OF DEHYDROGENASES WITH STABLE COENZYMES - The present invention relates to a method for stabilizing an enzyme by storing the enzyme in the presence of a stable coenzyme. The present invention further relates to an enzyme stabilized with a stable coenzyme, and to the use thereof in test elements for detecting analytes.06-16-2011
20100285564Anticalins - The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.11-11-2010
20110294189BIOMOLECULE POLYMER CONJUGATES AND METHODS FOR MAKING THE SAME - Methods for producing biomolecule-polymer conjugates, such as polypeptide-polymer conjugates, include attachment of an initiator agent to a biomolecule and in situ polymerization of a polymer from defined sites on the biomolecule. The conjugates may have desirable pharmacological properties and may be used therapeutically.12-01-2011
20090269825METHOD FOR STABILIZATION OF BIOLOGICAL MOLECULE AND COMPOSITION - The object is to provide a method for stabilization of a biological molecule and a composition, specifically a method for stabilization of an enzyme or a labeled antibody for use in a clinical diagnosis and a composition. Thus, disclosed is a method for stabilization of a biological molecule which is characterized by allowing (a) the biological molecule and (b) sericin and/or a hydrolysate or equivalence thereof to coexist with each other. Also disclosed is a composition having a biological molecule stabilized therein, which is characterized in that the components (a) and (b) coexist with each other in the composition. Further disclosed is a composition for stabilizing a biological molecule, which comprises sericin and/or a hydrolysate or equivalence thereof.10-29-2009
20110014676PROTEIN STABILIZATION - A method and formulation for temperature stabilization of proteins, such as antibodies, enzymes such as Taq poly-merase, restriction enzymes, and other diagnostic or therapeutic enzymes using a combination of first and second stabilizers.01-20-2011
20090298154Conjugated biological molecules and their preparation - Novel biologically active compounds of the general formula (I) in which one of X and X′ represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X′ represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X′ and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z12-03-2009
20120107903Mutant Glucose Dehydrogenase - A mutant glucose dehydrogenase having an amino acid sequence at least 80% identical to SEQ ID NO:3 and having glucose dehydrogenase activity, wherein amino acid residues corresponding to positions 326, 365 and 472 of said amino acid sequence are replaced with glutamine, tyrosine and tyrosine, respectively, and wherein said mutant glucose dehydrogenase shows an improved substrate specificity to glucose and a reduced reactivity to disaccharides.05-03-2012
20120107902Processes For Forming Amide Bonds And Compositions Related Thereto - The disclosure relates to methods for producing amide bonds and reagents related thereto. In some embodiments, the disclosure relates to methods of producing an amide comprising mixing an O-silylated thionoester and an amine under conditions such that an amide is formed. In another embodiment, the disclosure relates to mixing a thiolacid, a silylating agent, and an amine under conditions such that an amide is formed.05-03-2012
20110171714CRYSTAL STRUCTURE OF TAK1-TAB1 - The invention relates to molecules or molecular complexes which comprise binding pockets of TAK1 or its structural homologues. The invention relates to crystallizable compositions and crystals comprising TAK1. The present invention also relates to a data storage medium encoded with the structural coordinates of molecules and molecular complexes which comprise the TAK1 or TAK1-like ATP-binding pockets. The present invention also relates to a computer comprising such data storage material. The computer may generate a three-dimensional structure or graphical three-dimensional representation of such molecules or molecular complexes. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to TAK1 or homologues thereof.07-14-2011
20090263880MUTANT LUCIFERASE - An object of the present invention is to provide a mutant luciferase having luciferase activity with an altered emission spectrum. A specific amino acid residue(s) is substituted in a luciferase derived from 10-22-2009
20130217090CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE - Novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.08-22-2013
20110201080BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE - Compounds relating to attachment chemistries for binding biomolecules to a substrate surface are described. These include compounds of the following structure:08-18-2011
20110171716CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF - Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers.07-14-2011
20090275101Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.11-05-2009
20090280550Polymer-Factor IX Moiety Conjugates - Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.11-12-2009
20110171715BIOCOMPATIBLE POLYMER AND MAGNETIC NANOPARTICLE WITH BIOCOMPATIBILITY - The invention discloses a biocompatible polymer for covalently modifying magnetic nanoparticles. The biocompatible polymer may be coupled to a targeting agent and/or a fluorescent dye. The invention also discloses a magnetic nanoparticle with biocompatibilities comprising the biocompatible polymer.07-14-2011
20130217091Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo - The present invention concerns methods and compositions for PEGylated complexes of defined stoichiometry and structure. Preferably, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and a PEG moiety to an AD sequence, allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. Alternatively, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.08-22-2013
20120288913NOVEL FUSION PARTNERS FOR THE PURPOSE OF CRYSTALLIZING G-PROTEIN COUPLED RECEPTORS - GPCR-fusion partner proteins comprising G protein coupled receptors (GPCRs) of GPCRs and fusion partners such as rubredoxin, cytochrome b562 RIL (Bril, bRIL, BRIL), T4 lysozyme C-terminal fragment (Cterm-T4L), flavodoxin, or xylanase either substituted for some or all of the third intracellular loop of the GPCR between the fifth and sixth helix of the GPCR are described or attached to an terminus or C terminus of the GPCR. GPCR-fusion partner proteins in crystalline form, optionally of a quality suitable for x-ray crystallographic structure determination of the GPCR, are described. Methods of using fusion partners in GPCR-fusion partner proteins to support crystallization of GPCR-fusion partner proteins for x-ray crystallographic structure determination of the GPCR, are described. Methods of identifying other suitable fusion partners through screening of protein data banks are also described.11-15-2012
20110223645Multivalent Carriers of Bi-Specific Antibodies - Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.09-15-2011
20090081759NUCLEIC ACID ENCODING A NOVEL RIBONUCLEASE HAVING AN AMINO ACID SEQUENCE MADE UP OF THE AMINO ACID SEQUENCE OF A KNOWN RIBONUCLEASE AND AN N-TERMINAL LEADER SEQUENCE THAT IS AT LEAST ONE RESIDUE LONG - A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in United States Patent U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue or leader sequence.03-26-2009
20090081757Adsorbents Comprising Anthraquinone Dye-Ligends for the Separation of Biological Materials - A process for the separation of biological materials, such as dye-ligand affinity chromatography, wherein an adsorbent is used, which comprises a reaction product of certain reactive anthroquinone compounds and a substrate having a group capable of reaction with a reactive group in said reactive anthroquinone compounds to form a covalent bond.03-26-2009
20090104678METHOD OF PRODUCING POLYSACCHARIDE DERIVATIVES - A polysaccharide derivative having a high solubility in an aqueous solvent is produced. The production method of the present invention uses a compound shown by the general formula (1) as a condensing agent and allows a polysaccharide having a carboxyl group to react with an an organic compound having a functional group capable of condensing with the carboxyl group to prepare the polysaccharide derivative:04-23-2009
20090081756Nucleic acid-enzyme complex - The present invention provides a method for controlling cleavage of a target RNA by deoxyribozyme.03-26-2009
20090081758Chimeric Cytochrome P450 Proteins and Methods of Use - The present invention provides chimeric cytochrome P450 enzymes fused to heterologous reductase domains to generate single-component, self-sufficient, more cost-effective and catalytically more active biosynthetic P450 monooxygenases.03-26-2009
20120196346Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses - The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.08-02-2012
20110143417Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities - The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. The disclosed methods and compositions provide a simple, easy to purify way to obtain any binary compound attached to any monomeric compound, or any trinary compound.06-16-2011
20100261248Pharmaceutical Composition Comprising An Immunoglobulin FC Region as a Carrier - Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.10-14-2010
20100261247Active surface coupled polymerases - Active surface coupled polymerases, surfaces that include such polymerases, and methods of making and using surface-attached polymerases are provided.10-14-2010
20100227374PROTEIN STABILIZATION BY DOMAIN INSERTION INTO A THERMOPHILIC PROTEIN - A strategy to improve protein stability by domain insertion. TEM 1 beta-lactamase (BLA) and exo-inulinase, as model target enzymes, are inserted into a hyperthermophilic maltose binding protein from 09-09-2010
20110059502MULTIPLE DOMAIN PROTEINS - Described herein are methods and compositions for generating and using fusion proteins.03-10-2011
20120244595ARTIFICIAL PEPTIDOGLYCAN LYSING ENZYMES AND PEPTIDOGLYCAN BINDING PROTEINS - The present invention relates to recombinant polypeptides having the activity of binding and lysing of bacteria, comprising at least one enzymatically active domain and at least two bacterial cell binding domains. The present invention further relates to recombinant polypeptide having the activity of binding bacteria, comprising at least two bacterial cell binding domain. Further the present inventions relates to nucleic acid molecules comprising a nucleotide sequence encoding the recombinant polypeptides, vectors and host cells.09-27-2012
20100255558SUPRAMOLECULAR BIOCONJUGATES - The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjugates. Supramolecular bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecular bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes. The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit.10-07-2010
20120034671Protein Matrix For Light-Initiated Electron Transfer - The present invention provides selective modification of polypeptide sequences with electron transfer moieties. The resulting polypeptide assemblies represent a novel class of electron transfer complexes that are capable of transferring electrons over very long distances at fast rates. These complexes possess unique structural features which enable the production of bioconductors and photoactive probes.02-09-2012
20120142070REHYDRATABLE MATRICES FOR DRY STORAGE OF TAQ POLYMERASE IN A MICROFLUIDIC DEVICE - Formulations for dry storage of PCR reagents are described. These formulations find use in manufacture of self-contained microfluidic card devices for PCR clinical testing in which the reagents are reconstituted at the point of testing. In these cards, TAQ polymerase is stored “on-board” in vitrified dry form without lyophilization or freezing, and is reconstituted by either the sample or a sample eluate during the assay.06-07-2012
20100221807CELLULASE ENZYME AND METHOD FOR PRODUCING THE SAME - This invention provides a cellulase enzyme derived from intestinal symbiotic protists of insects selected from the group consisting of 09-02-2010
20130137158LIGAND FUNCTIONALIZED POLYMERS - Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.05-30-2013
20130137159LIPASE-CONTAINING POLYMERIC COATINGS FOR THE FACILITATED REMOVAL OF FINGERPRINTS - A substrate or coating is provided that includes a lipase with enzymatic activity toward a component of a fingerprint. Also provided is a process for facilitating the removal of fingerprints is provided wherein an inventive substrate or coating including a lipase is capable of enzymatically degrading of one or more components of the fingerprint to facilitate fingerprint removal from the substrate or said coating. Applying heat to the substrate or coating increases the rate of fingerprint removal.05-30-2013
20110151536THROMBIN ACTIVATOR COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions.06-23-2011
20110151538AFFINITY PURIFICATION BY COHESIN-DOCKERIN INTERACTION - The present invention is directed to truncated dockerin polypeptides, recombinant polypeptides and affinity systems comprising the truncated dockerin polypeptide, methods of generating same, and methods of use thereof to purify, isolate, and detect molecules of interest.06-23-2011
20100015684FACTOR VII: REMODELING AND GLYCOCONJUGATION OF FACTOR VII - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.01-21-2010
20110129894SECRETION OPTIMIZED MICROORGANISM - Proteins having a cofactor can be secreted in an improved manner in a microorganism belonging to the genus 06-02-2011
20110244545Polymeric carriers for immunohistochemistry and in situ hybridization - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.10-06-2011
20110244546Internalizing Anti-CD74 Antibodies and Methods of Use - The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.10-06-2011
20110244544Polymeric carriers for immunohistochemistry and in situ hybridization - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.10-06-2011
20090203104TAB Molecules - The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.08-13-2009
20110081702Method for the Production of Proteins - The present invention relates to a process for the purification of a protease.04-07-2011
20100129890Cytochrome P450 enzyme complexes and methods of treatment using the same - The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.05-27-2010
20110151537Synthetic Catalysts that Separate CO2 from the Atmosphere and Gas Mixtures - The creation of a catalyst that can be used for a wide variety of applications including the steps of developing preliminary information regarding the catalyst, using the preliminary information to produce a template of the catalyst, and using the template of the catalyst to produce the catalyst.06-23-2011
20120202263Bioactive Macromers and Hydrogels and Methods for Producing Same - The invention concerns macromers, having a molecular weight of at least 2 kDa, comprising at least one unit of the formula P-(protein-P)08-09-2012
20120202264INHIBITORS OF IL2-INDUCIBLE T-CELL KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.08-09-2012
20120202262PROCESS FOR PRODUCTION OF AN ENZYME PRODUCT - The invention relates to a process for production of an enzyme product having a plurality of enzyme activities obtained by fermentation of an 08-09-2012
20120276609Stabilization Of Perhydrolases - Disclosed herein are enzyme powders comprising a spray-dried formulation of at least one CE-7 esterase, at least one oligosaccharide excipient, and optionally at least one surfactant. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned enzyme powders. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.11-01-2012
20110053244NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS - A novel protein delivery system to generate induced pluripotent stem (iPS) cells is described. The delivery system comprises a construct with a receptor binding domain that recognizes a receptor in a somatic cell, a translocation domain that allows the transfer of an inducer into the cytosolic space, and a cargo bearing domain to which the inducer is attached and facilitates transfer of the inducer into the cell.03-03-2011
20110136201HETEROCYCLE-SUBSTITUTED XANTHENE DYES - The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.06-09-2011
20100323421METHOD FOR CHEMICALLY MODIFYING BIOPOLYMER AND POLYPEPTIDE - It is an object of the present invention to provide a method for chemically modifying biopolymer and polypeptide with a hydrophobic compound or a compound which causes degradation or reaction under basic condition. The present invention provides a method for producing a chemically modified biopolymer or polypeptide, wherein a biopolymer or polypeptide is chemically modified in a reaction solution containing an organic fluorine compound.12-23-2010
20100323420REGULATED APOPTOSIS - We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.12-23-2010
20100323422PEG-Urate Oxidase Conjugates and Use Thereof - A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.12-23-2010
20100330645ONE POT DESIALYLATION AND GLYCOPEGYLATION OF THERAPEUTIC PEPTIDES - The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.12-30-2010
20090111158IMMOBILIZED MICROBIAL NITRILASE FOR PRODUCTION OF GLYCOLIC ACID - The present invention provides a process for preparing an enzyme catalyst having nitrilase activity for hydrolysis of glycolonitrile to glycolic acid with improved retention of recovered catalyst activity in consecutive batch reactions with catalyst recycle, said process comprising pretreating the enzyme catalyst with glutaraldehyde. The glutaraldehyde-pretreated enzyme catalyst has improved specific activity when compared to non-glutaraldehyde-pretreated enzyme catalysts, and thereby, has improved overall catalyst activity and productivity.04-30-2009
20090197317TSG-Like Gene - A gene encoding a novel protein that is homologous to 08-06-2009
20110189753Intracellular Production of a Nuclease - Methods and compositions are provided that relate to obtaining a recombinant DNA and RNA cleaving nuclease. This involves the over-expression of a fusion protein between maltose-binding protein and a truncated nuclease in a soluble form in the cytoplasm of a host cell from which it can be readily extracted.08-04-2011
20110189754FUSION PROTEIN COMPRISING AN E. COLI CHAPERONE PROTEIN AND A HUMAN CHAPERONE PROTEIN - The invention discloses the cloning, expression and uses of a chimeric fusion protein with superior chaperone and folding activities compared to the wild type chaperones. This invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for an FK506 binding protein (FKBP) or an FK506-binding-protein-like domain (FKBP-like domain). In particular, this invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for a human FKBP type peptidyl-prolyl-cis/trans isomerase (PPIase), methods of producing these chimeric fusion proteins and their uses as folding helpers in the production of other proteins and in the process of the production of vaccines or pharmaceuticals, and as folding helpers for performing immunoassays.08-04-2011
20110262994NOVEL REAGENTS AND METHOD FOR CONJUGATING BIOLOGICAL MOLECULES - A compound of the general formula X-[Q-W—(CH═CH)10-27-2011
20110262993METHOD FOR PREPARING A CELLULAR CARBON MONOLITH COMPRISING A HIERARCHISED POROUS NETWORK - A carbon or ceramic monolithic materials with an M2 (macroporous/microporous) hierarchised porous structure is provided as well as method for preparing said materials using a macro/meso/microporous silica cavity. Such materials may be used, in particular for the production of hydrogen purifiers, supercapacitors or electrodes, or else for carrying out catalysed chemical reactions in a heterogeneous phase.10-27-2011
20110262991Living Copolymer-Protein/Peptide Hybrids for Biomedical Applications - Water soluble polymers having formula I: Y-(L10-27-2011
20080299638Pharmaceutical Composition and Method of Treating Hepatitis with Arginases - The invention discloses methods for treating hepatitis with human arginase I modified by polyethylene glycol and uses of it in manufacturing of a medicament.12-04-2008
20120231520NOVEL FUSION PROTEINS AND METHOD OF EXPRESSION THEREOF - The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins.09-13-2012
20120149084FUSION PROTEINS - The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.06-14-2012
20120040432METHODS AND MATERIALS FOR DELIVERING MOLECULES - This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.02-16-2012
20120040431Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.02-16-2012
20120040430Compositions useful for detection or quantification of desirable target molecules, novel dyes, composite dyes, and oligonucleotides or polynucleotides comprising such dyes - The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties.02-16-2012
20120149083PEG-Urate Oxidase Conjugates and Use Thereof - A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.06-14-2012
20120149085FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES - Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.06-14-2012
20120149082Method For The Preparation Of Cross-Linked Enzyme Aggregates With Improved Properties - The invention relates to a method for the preparation of hybrid cross-linked enzyme-silica aggregates including the steps of taking up enzyme molecules in a solvent, precipitating the enzyme molecules using a precipitation agent, and adding an alkoxysilane and crosslinking the mixture of alkoxysilane and precipitated enzyme aggregates, using a crosslinking agent comprising an aldehyde, to obtain hybrid crosslinked enzyme-silica aggregates.06-14-2012
20130157337TEMPLATE-DIRECTED ASSEMBLY OF RECEPTOR SIGNALING COMPLEXES - Transmembrane receptors in the signaling pathways of bacterial chemotaxis systems influence cell motility by forming noncovalent complexes with the cytoplasmic signaling proteins to regulate their activity. The requirements for receptor-mediated activation of CheA, the principal kinase of the 06-20-2013
20100221808POLYSIALIC ACID DERIVATIVES - A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.09-02-2010
20110318808Engineered Plant Cysteine Proteases and Their Uses - The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.12-29-2011
20110318809METHOD OF SCREENING PLACENTAL PROTEINS RESPONSIBLE FOR PATHOPHYSIOLOGY OF PREECLAMPSIA, AND MARKER FOR EARLY DIAGNOSIS AND PREDICTION OF PREECLAMPSIA - The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas.12-29-2011
20120003714BLENDS CONTAINING PROTEASES - Described are compositions, in particular lyophilizates, containing proteolytic enzymes, and methods for producing the compositions. Typically these compositions contain one or more proteases with collagenase activity and a neutral protease, for example, thermolysis. The compositions are free of acetate salts. Surprisingly, such compositions can be dissolved in water more rapidly than lyophilized protease mixtures of the state of the art.01-05-2012
20120003713Polymerase Enhancing Factor (PEF) Extracts PEF Protein Complexes Isolated PEF Proteins and Methods for Purifying and Identifying - The invention provides novel extracts, proteins, and complexes that improve the polymerization activity of nucleic acid polymerases. Included within the aspects of the invention are methods for identifying compositions with a polymerase enhancing activity, methods for purifying and using these compositions, and specific extracts, proteins, and complexes that function to enhance polymerase activity. As an example, specifically described is nucleotide and amino acid sequence information for a 01-05-2012
20120009646CHEMICALLY MODIFIED CARBONIC ANHYDRASES USEFUL IN CARBON CAPTURE SYSTEMS - The present disclosure relates to chemically modified carbonic anhydrase polypeptides and soluble compositions, homogenous liquid formulations comprising them. The chemically modified carbonic anhydrase polypeptides have improved properties relative to the same carbonic anhydrase polypeptide that is not chemically modified including the improved properties of increased activity and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides methods of preparing the chemically modified polypeptides and methods of using the chemically modified polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering.01-12-2012
20110165649METHODS AND COMPOSITIONS TO IMPROVE THE HEALTH OF PLANTS, ANIMALS AND MICROBES BY MANIPULATING PROTEIN ENTRY INTO SYMBIONTS AND THEIR HOSTS - Fusion constructs with i) a domain that is specific for binding, on the surface of a cell, a lipid that is characteristic of the cell, and ii) a domain or agent that possesses an activity of interest that impacts the cell, are provided. Binding of the fusion construct to the characteristic lipid results in attachment of the construct to the cell and 1) expression of the activity of interest at the cell surface or, 2) entry of the construct into the cell, so that the activity of interest is expressed inside the cell. The cell may be a pathogen, cancer cell or other pathological cell displaying a characteristic lipid, and the domain or agent may be toxic or inhibitory to the cell. Alternatively, the cell may be non-pathogenic and the activity of interest may elicit a desired response from the cell, e.g. cell division, up regulation of a gene sequence, etc.07-07-2011
20110165648Co-crystal structure of factor D and anti-factor D antibody - The present invention is directed towards the co-crystal structure of Factor D and an anti-Factor D antibody or an antigen binding fragment thereof.07-07-2011
20110165647NANOPARTICLE CONJUGATES - A nanoparticle conjugate comprising a nanoparticle having one or more peptide-ol compounds and one or more polyethylene glycol (PEG) compounds attached thereto. A method of producing the nanoparticle conjugate is also described.07-07-2011
20110165650Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A)07-07-2011
20120064600ANTI-5T4 ANTIBODIES AND USES THEREOF - Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.03-15-2012
20120208258CONJUGATE OF CATECHOL-MODIFIED POLYETHYLENE GLYCOL WITH PROTEIN OR PEPTIDE AND PREPARATION METHOD THEROF - The present invention relates to a conjugate of a protein or peptide with a polyethylene glycol derivative having catechol, wherein the protein or peptide is mono-PEGylated at the N-terminal with the polyethylene glycol derivative, and to a preparation method thereof. According to the invention, the catechol-PEG derivative can be site-specifically conjugated with the N-terminal amine group of a protein or peptide, so that a homogeneous polyethylene glycol-protein or -peptide conjugate can be obtained in high yield. Unlike a prior art conjugate, the conjugate obtained according to the invention allows the decrease in the activity of the protein to be minimized without chemically modifying the protein, and thus the conjugate has an excellent pharmacological effect. Also, because the conjugate is homogeneous, the process for preparing the conjugate can be simplified. Moreover, the conjugate has uniform biological efficacy in vivo and shows strong resistance to hydrolysis and thus a long in vivo duration time. Accordingly, the conjugate has the effect of increasing the in vivo efficacy and stability of the protein drug.08-16-2012
20120064599HYBRIDIZATION LINKERS - The invention provides method of covalently coupling two or more moieties, the method comprising: (a) providing a first moiety having covalently attached thereto (i) at least one first linker comprising a first hybridizable region and (ii) at least one first group capable of forming a covalent bond; (b) providing a second moiety having covalently attached thereto (i) at least one second linker comprising a second hybridizable region capable of hybridizing to the first hybridizable region and (ii) at least a second group capable of forming a covalent bond with the first group; (c) contacting the first and second moieties under conditions that allow the first and second hybridizable regions to hybridize and link the moieties; and (d) exposing the linked moieties to conditions that allow the formation of a covalent bond between the first and second groups.03-15-2012
20120070875Amino Acid Sequences which Enhance Peptide Conjugate Solubility - The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases.03-22-2012
20120070874Method for recycling enzyme - In saccharification of cellulose, chimeric β-glucosidase having a region exhibiting thermophilic bacteria-derived β-glucosidase activity and a module combinable to cellulose is used along with cellulosome, and at the completion of saccharification of cellulose, a cellulosic substrate is added to make the chimeric β-glucosidase and cellulosome attach to the cellulosic substrate for separation.03-22-2012
20120156750COMPOSITIONS AND METHODS FOR DEHYDRATED STORAGE OF ON-BOARD REAGENTS IN MICROFLUIDIC DEVICES - Manufacturing methods and compositions are described for production of self-contained microfluidic cartridge devices with on-board reagents for molecular biological testing. Sensitive reagents are stored in dry form without lyophilization or freezing, and reconstituted at the point of use with either a biological sample or a sample eluate at the point of use. Manufacturing methods include sheet and roll fabrication processes where the reagents are printed in place and sealed within individual microfluidic cartridges before gel vitrification.06-21-2012
20110086404METHOD FOR MONITORING, DIAGNOSING, AND SCREENING CANCER THROUGH MEASURING THE CONCENTRATION OF DES-R PROTHROMBIN ACTIVATION PEPTIDE FRAGMENT F2 (DES-R F2) IN A SERUM - The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.04-14-2011
20110091957PROTEIN-POLYMER CONJUGATES AND SYNTHESIS THEREOF - A method of synthesizing a protein-polymer conjugate includes the steps: covalently attaching at least one controlled radical polymerization initiator to a protein to form a protein-initiator composition; and mixing the protein-initiator composition with at least one monomer which undergoes controlled radical polymerization in the presence of the protein-initiator composition under conditions suitable to initiate the controlled radical polymerization.04-21-2011
20130011901CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE - The invention aims in establishing a method for modifying biomolecules using a reaction that efficiently modifies biomolecules and is widely applicable. The invention thus provides a cyclic compound containing two triazole rings formed by adding and ligating an azide compound possessing an azido group to each of the two carbon-carbon triple bond sites of an eight-membered cyclic skeleton of a cyclic diyne compound by a double click reaction; a method for producing a cyclic compound using a double click reaction; and a method for modifying biomolecules.01-10-2013
20130011900NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.01-10-2013
20110104783STEREOISOMER PEPTIDES, LIGAND-TARGETED MULTI- STEREOISOMER PEPTIDE POLYMER CONJUGATES, AND USES THEREOF - The invention provides compounds of the formula Poly-([SP-LI]n-PL-L2) including a collection of 152 peptides useful to create the compounds, and their uses thereof for the treatment of a variety of mammalian diseases. The compound, a novel ligand-targeted multi-stereoisomer peptide polymer conjugate, comprises two or more stereoisomer peptides and a peptide-ligand conjugated via linkers to a biocompatible hydrophilic polymer, preferably HPMA. The increased stability and solubility of the compound carrying the stereoisomer peptides and a peptide-ligand provide ideal pharmaceutical properties including the delivery by the polymer of the peptides into the target cells. The compounds of the invention are useful therapeutics for the treatment of a variety of mammalian diseases. Examples of such diseases in human patients include abnormal angiogenesis, pathological conditions of the eye, cancer, metastasis, diabetes, Alzheimer's and Parkinson's diseases, brain and neurodegenerative disorders, bipolar disorder, and diseases caused by aging and pathogen agents, to name a few.05-05-2011
20110104782CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF - The present invention provides crystalline molecules or molecular complexes which comprise binding pockets of Aurora-2 or its homologues. The invention also provides crystals comprising Aurora-2. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates of Aurora-2 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the molecule or molecular complex. This invention also provides methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention provides methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to Aurora-2 or homologues thereof.05-05-2011
20120122180INCORPORATION OF TYPE III POLYKETIDE SYNTHASES INTO MULTIDOMAIN PROTEINS OF THE TYPE I AND III POLYKETIDE SYNTHASE AND FATTY ACID SYNTHASE FAMILIES - Recombinant fusion proteins in which intermediates are covalently bound to the fusion proteins and transferred between domains of the fusion proteins are provided. The fusion proteins include proteins having type I polyketide or fatty acid synthase domains fused with type III polyketide synthase domains. Methods of making such recombinant fusion proteins and methods using such proteins to produce polyketide and other products are described.05-17-2012
20120122181METHOD FOR DETERMINING ANTAGONIST ACTIVITY TO A CYTOKININ RECEPTOR - The present invention provides a method for analyzing agonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and, a method for analyzing antagonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance and a substance having agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced.05-17-2012
20120122179MEANS FOR PURIFYING A PROTEIN OF BLOOD PLASMA AND METHODS FOR IMPLEMENTING SAME - An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein.05-17-2012
20100075392METHOD FOR REMOVING ORGANIC SOLVENT - An object of the present invention is to provide a method for efficiently removing a residual organic solvent in a biopolymer structure. The present invention provides a method for removing an organic solvent contained in a biopolymer structure from the structure, (1) wherein the structure is placed in an atmosphere containing a solvent other than the organic solvent so as to remove the organic solvent, or (2) wherein the organic solvent is removed by washing the structure with a solution mainly containing water, or (3) wherein the structure contains a hydrophilic compound.03-25-2010
20100248326STABILIZATION OF THERMOLYSIN IN AQUEOUS SOLUTION - The present invention deals with the proteolytic enzyme thermolysin which tends to be unstable in aqueous solution. The invention provides methods and compositions to enhance the stability of dissolved thermolysin in aqueous solution. Thermolysin, crude thermolysin or a lyophilisate containing thermolysin and one or more salts, is contacted with an aqueous buffer with a low salt concentration and a first solution is formed. Subsequently, a further salt in solid form is added and dissociated, thereby forming a second solution comprising thermolysin in a stabilized form.09-30-2010
20120129237POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS - The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.05-24-2012
20120164708STABILIZED ENZYME COMPOSITIONS - The present invention relates to a composition comprising an enzyme and octanol. Additionally, the present invention relates to a composition comprising a transition metal ion.06-28-2012
20120231521Transducible Polypeptides For Modifying Metabolism - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.09-13-2012
20120214220XYLANASE COMPOSITION AND METHOD FOR MANUFACTURING THE SAME - A xylanase composition and a method for manufacturing the xylanase composition are provided, wherein the xylanase composition comprises a xylanase and a stabilizer, and the xylanase is from an anaerobic fungus, the stabilizer comprises a polyol, and the content of the polyol is at least 40 wt %, based on the total weight of the xylanase composition.08-23-2012
20100184184Production of Conjugates - Disclosed is a method for indirectly coupling a small molecule ligand to a molecule to be labelled with the ligand, the method comprising the step of: contacting a scaffold molecule, to which is attached at least one small molecule ligand, with the molecule to be labelled, the scaffold molecule having at least one group which is reactive towards a receiver moiety present or formed in situ on the molecule to be labelled, so as to forma bond between the scaffold molecule and the molecule to be labelled, thereby indirectly coupling the small molecule ligand to the molecule to be labelled.07-22-2010
20120135495NEUROTOXINS WITH ENHANCED TARGET SPECIFICITY - Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.05-31-2012
20100173384METHODS FOR PROTEIN LABELING BASED ON ACYL CARRIER PROTEIN - A method for labeling acyl carrier protein (ACP) fusion proteins with a wide variety of different labels is disclosed. The method relies on the transfer of a label from a coenzyme A type substrate to an ACP fusion protein using a holo-acyl carrier protein synthase (ACPS) or a homologue thereof. The method allows detecting and manipulating the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such labels are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilization of the fusion protein.07-08-2010
20100173383Nuclear Factor Of Activated T Cells Receptor - The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.07-08-2010
20100173381CRYSTAL STRUCTURES OF HIV-1 PROTEASE INHIBITORS BOUND TO HIV-1 PROTEASE - Described herein are methods for rational design of inhibitors of HIV-1 protease, and crystal structures of HIV-1 protease inhibitors bound to HIV-1 protease.07-08-2010
20100173382HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES - Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.07-08-2010
20120171747SIGNAL AMPLIFICATION MICROSPHERES, THEIR USE IN ONE-STEP AND MULTI-STEP ANALYTICAL AMPLIFICATION PROCEDURES AND METHODS FOR THEIR PRODUCTION - The present invention relates to microspheres comprising protein signal precursor molecules, or a carrier protein bonded to signal precursor molecules, wherein said signal precursor molecules are activatable to generate a detectable signal whilst remaining bonded to the carrier protein. Also disclosed is a method of making such microspheres comprising the steps of mixing protein molecules with a matrix former in solution; adding a reducing reagent to the mixture; removing the reducing reagent; and removing the matrix former to leave microspheres of protein molecules. Also disclosed are bioassay methods using the microspheres to provide signal amplification, including an amplification cycling procedure.07-05-2012
20120252092CLOSTRIDIUM HISTOLYTICUM RECOMBINANT COLLAGENASES AND METHOD FOR THE MANUFACTURE THEREOF - The present invention relates to the production of recombinant collagenases, and in particular describes a method for the production of recombinant 10-04-2012
20120178139ERYTHROCYTE-BINDING THERAPEUTICS - Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.07-12-2012
20120178140Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptor Systems - The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.07-12-2012
20120178138MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY - The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake.07-12-2012
20100273233AMYLOID SPECIFIC PEPTIDES AND USES THEREOF - Phage peptide display technology was used to identify peptides that bind specifically to the amyloid form of the Aβ10-28-2010
20120083025Hybrid Enzymes - The present invention relates to hybrid polypeptides having a first amino acid sequence having endo-amylase activity and a second amino acid sequence having carbohydrate binding activity. The present invention also relates to the use of the hybrid polypeptides in starch processing and baking.04-05-2012
20120190098FLUOROGENIC COMPOUNDS CONVERTED TO FLUOROPHORES BY PHOTOCHEMICAL OR CHEMICAL MEANS AND THEIR USE IN BIOLOGICAL SYSTEMS - Fluorophores derived from photoactivatable azide-pi-acceptor fluorogens or from a thermal reaction of an azide-pi-acceptor fluorogen with an alkene or alkyne are disclosed. Fluorophores derived from a thermal reaction of an alkyne-pi-acceptor fluorogen with an azide are also disclosed. The fluorophores can readily be activated by light and can be used to label a biomolecule and imaged on a single-molecule level in living cells.07-26-2012
20120190097ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME - The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.07-26-2012
20120190096MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN - The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.07-26-2012
20120258515Cytolytic RTX-Toxin From Gallibacterium Anatis - The present invention relates to the field of animal health and in particular the causative agent of a new bacterial poultry disease caused by 10-11-2012
20110124081NUCLEAR FACTOR OF ACTIVATED T CELLS RECEPTOR - The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (“NEAT”) receptor, and related compositions and methods.05-26-2011
20120231519Molecular Surface Design of Tyrosine-Derived Polycarbonates for Attachment of Biomolecules - Methods for constructing tyrosine-derived biotinylated polymers. Biotinylated polymers and polymer scaffolds constructed with the biotinylated polymers are also disclosed.09-13-2012
20110039324COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.02-17-2011
20120270296ISOTOPE-DOPED NANO-STRUCTURE AND ISOTOPE LABELED STRUCTURE USING THE SMAE - An isotope-doped nano-structure is provided. The isotope-doped nano-structure includes at least one isotope-doped nano-structure segment having at least two isotopes of the element. The at least two isotopes of the element are mixed uniformly in a certain proportion. The isotope-doped nano-structure can be used for isotope labeling one type of the unlabeled structures such as DNAs, proteins, glucoses, gluconic acids, starches, biotin enzymes, sorbitols, or organic amines. An isotope labeled structure is also provided.10-25-2012
20110236952NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF - The invention relates to compounds of formula (I′):09-29-2011
20100233779Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.09-16-2010
20120276608Multivalent Immunoglobulin-Based Bioactive Assemblies - The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.11-01-2012
20120329130INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.12-27-2012
20120329128FORMULATIONS OF RECOMBINANT FURIN - The present application provides stabilized formulations of furin (e.g., rfurin) containing a sugar, sugar alcohol, and/or non-ionic surfactant. As compared to non-stabilized compositions, the furin formulations disclosed herein retain greater amounts of furin activity and monomeric furin content, while reducing furin aggregation when stored and/or subjected to mechanical stress. Also provided are methods for stably diluting furin (e.g., rfurin) compositions.12-27-2012
20120329126HYBRID POLYMERASES HAVING THE ABILITY TO PRODUCE LONG AMPLICONS - The present invention provides DNA polymerases having increased efficiency of amplification of long amplicons. The present invention also provides for methods of amplifying target nucleic acid molecules with the DNA polymerases for increasing the efficiency of amplification of long amplicons.12-27-2012
20120329127THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME - The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.12-27-2012
20120329129MAGNETIC NANOPARTICLE WITH BIOCOMPATIBILITY - A magnetic nanoparticle is provided in the disclosure. The magnetic nanoparticle includes a magnetic nanoparticle; a biocompatible polymer of the following formula (II) covalently coupled to the magnetic nanoparticle, wherein R12-27-2012
20120100593Crystals of membrane proteins - A polypeptide in crystalline form comprises a G-protein coupled receptor (GPCR) with an IC3 loop substituted by an amino acid residue sequence of lysozyme.04-26-2012
20120135496Protein Belonging to the TNF Superfamily Involved in Signal Transduction, Nucleic Acids Encoding Same and Methods of Use Thereof - A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo. Preferably, the method of the present invention results in increasing immune response towards the antigen in the animal.05-31-2012
20110159566Methods and Reagents for Preparing Multifunctional Probes - Multifunctional probes are synthesized in a single step using peptide scaffold-based multifunctional single-attachment-point reagents. To obtain multifunctional probes using the methods of the invention, a substrate (e.g., a nanoparticle, polymer, antibody, protein, low molecular weight compound, drug, etc.) is reacted with a multifunctional single-attachment-point (MSAP) reagent. The MSAP reagents can include three components: (i) a peptide scaffold, (ii) a single chemically reactive group on the peptide scaffold for reaction of the MSAP with a substrate having a complementary reactive group, and (iii) multiple functional groups on the peptide scaffold. The peptide scaffold can include any number of residues; however, for ease of synthesis and reproducibility in clinical trials, it is preferred to limit the residues in the peptide to 20 or less. The reagent can be prepared to yield a predetermined stoichiometric ratio of the functional groups on the scaffold such that the probe has a fixed stoichiometric ratio of the functional groups.06-30-2011
20110159565REAGENTS AND PROCESSES FOR STABILIZING ALKALINE PHOSPHATASE OR CONJUGATES THEREOF - The present disclosure relates to stabilizers for alkaline phosphatase or conjugates thereof, a process for preparing a stabilizer, and a method for stabilizing alkaline phosphatase or conjugates thereof with a stabilizer. The present disclosure also relates to a reagent of alkaline phosphatase or conjugates thereof as well as to a process for preparing the same. In another aspect, the present disclosure relates to a kit comprising the stabilizers disclosed herein and alkaline phosphatase or conjugates thereof. The stabilizer disclosed herein can stabilize alkaline phosphatase or conjugates thereof for a prolonged period of time, extending their shelf-life.06-30-2011
20110159564METHOD FOR STABILIZING COENZYME AND COMPOSITION THEREOF - Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme.06-30-2011
20130023027FUSION PROTEINS OF BACTERIAL LUCIFERASE AS MULTICOLOR LUMINESCENT SENSORS - The present invention discloses systems and methods for altering the color of bacterial bioluminescence via a fusion protein complex by fusing 01-24-2013
20130171714PURO-DHFR QUADRIFUNCTIONAL MARKER AND ITS USE IN PROTEIN PRODUCTION - This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).07-04-2013
20130171715Phenyl Xanthene Dyes - Fluorescent phenyl xanthene dyes are described that comprise any fluorescein, rhodamine or rhodol comprising a particular C9 phenyl ring. One or both of the ortho groups on the lower C9 phenyl ring is ortho substituted with a group selected from alkyl, heteroalkyl, alkoxy, halo, haloalkyl, amino, mercapto, alkylthio, cyano, isocyano, cyanato, mercaptocyanato, nitroso, nitro, azido, sulfeno, sulfinyl, and sulfino. In one embodiment, halo and/or hydroxy groups are used. Optimal dyes contain a lower C9 phenyl ring in which both ortho groups are the same and the lower ring exhibits some form a symmetry relative to an imaginary axis running from the phenyl rings point of attachment to the remainder of the xanthene dye through a point para to the point of attachment. The phenyl xanthene dyes may be activated. Furthermore, the phenyl xanthene dyes may be conjugated to one or more substances including other dyes. The phenyl xanthene dyes are useful for a number of purposes, including labels for use in automated DNA sequencing as well the formation of fluorescent “bar codes” for polymeric particles used in the multiplexed analysis of analytes.07-04-2013
20130177960METHODS AND COMPOSITIONS FOR REGULATION OF TRANSGENE EXPRESSION - Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.07-11-2013
20110262992METHOD FOR STABILIZING LABELED ANTIBODY - The present invention relates to a method for stabilizing a labeled antibody in a solution, in which the labeled antibody is stabilized by allowing the labeled antibody to be present together with at least one of amino acid and a derivative thereof in the solution.10-27-2011
20110269210ALPHA-AMYLASE VARIANTS WITH ALTERED PROPERTIES - Disclosed are compositions comprising variants of alpha-amylase that have alpha-amylase activity and that exhibit altered properties relative to a parent AmyS-like alpha-amylase from which they are derived. The compositions generally comprise at least one of an additional enzyme, a detergent,.a surfactant, a chelator, an oxidizing agent, an acidulant, an alkalizing agent, a source of peroxide, a source of hardness, a salt, a detergent complexing agent, a polymer, a stabilizing agent, or a fabric conditioner. Also disclosed are detergent formulations comprising the variants. Methods of using the compositions for desizing woven material and washing or cleaning items, such as dishes or laundry, are disclosed. Kits related thereto are also provided.11-03-2011
20130177961MULTI-ARMED, MONOFUNCTIONAL, AND HYDROLYTICALLY STABLE DERIVATIVES OF POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS FOR MODIFICATION OF SURFACES AND MOLECULES - Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure07-11-2013
20130115674Human Monoclonal Antibodies to Human Nucleolin - The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysi-ology of the disease.05-09-2013
20130095547METHOD FOR SELECTIVE CONJUGATION OF ANALYTES TO ENZYMES WITHOUT UNWANTED ENZYME-ENZYME CROSS-LINKING - A method of preparing an analyte-enzyme conjugate where the enzyme contains free, surface-accessible carboxyl moieties without generating undesired, cross-linked enzymes, while preserving the functionality of the enzyme. The method involves treating an enzyme with a blocking agent such that the free carboxyl moieties become non-reactive prior to the conjugation reaction with the desired analyte. The invention is further directed to analyte-enzyme conjugates prepared by the inventive method and to kits which contain an analyte-enzyme conjugate prepared by the methods herein for the detection and/or quantitation of an analyte in a sample.04-18-2013
20130095548ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION - Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.04-18-2013
20130102049REMOVABLE SACCHARIDE-BENZIMIDAZOLE (BIM) TAGS AND CONJUGATES THEREOF VIA 1H-POSITION OF THE BENZIMIDAZOLES - Novel method and reagents for generating reversibly tagged saccharides, aldehydes, carboxyl acids, or orthoacetates useful in analytical and diagnostic applications are disclosed. Saccharides are coupled at the reducing end to tagging moieties comprising a reagent selected from a ortho-diaminobenzoic(DAB)-peptide, an aldo-imidazole or N-methylated aldo-imidazole, or an ortho-phenyldiamine (OPD) or substituted OPD. The tagged saccharide further comprising detectable or functional groups coupled to the tagging moiety are provided. Kits and reagents for chromatography and mass spectrometry are disclosed.04-25-2013
20130130348Polymers for Functional Particles - A method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. The nanoparticle may contain a drug. The moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other methods use such libraries, use or administer such polymeric conjugates, or promote the use of such polymeric conjugates. Kits involving such polymeric conjugates are also described.05-23-2013
20130130347CONSTRUCTS AND METHODS FOR THE ASSEMBLY OF BIOLOGICAL PATHWAYS - The present invention is directed to a synthetic nucleic acid scaffold comprising one or more subunits, each subunit comprising two or more different protein-binding sequences coupled together. The present invention further relates to systems and methods for assembling a synthetic biological pathway and producing a biological pathway product or a precursor product using the synthetic nucleic acid scaffold.05-23-2013
20130130350OBLIGATE HETERODIMER VARIANTS OF FOKI CLEAVAGE DOMAIN - Disclosed are methods of making and using engineered FokI cleavage domain variants. Also disclosed are methods, compositions and fusion proteins containing obligate heterodimers of engineered FokI cleavage domain variants and DNA binding domains, such as zinc finger protein (ZFP) domains and transcription activator-like effector (TALE) domains.05-23-2013
20130130349COOPERATIVE AND DYNAMIC ASSEMBLY OF AFFINITY COMPLEXES - The invention generally relates to the field of immunochemistry including antibody therapy, diagnostics, and basic research and specifically relates to the area of alternatives to natural antibodies including artificial antibodies or antibody mimics. The invention relates particularly to the cooperative assembly of stable affinity complexes.05-23-2013
20130143294NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS - The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.06-06-2013
20130143295AMYLASES AND GLUCOAMYLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - In one aspect, the invention is directed to polypeptides having an amylase and/or glucoamylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of polysaccharide, oligosaccharide or starch into sugars. In one aspect, the invention provides delayed release compositions comprising an desired ingredient coated by a latex polymer coating. In alternative embodiments, enzymes are used to make biofuels, e.g., ethanol, butanol, propanol, or a gasoline-ethanol mix, including a bioethanol, biopropanol, biobutanol, or a biodiesel, or for any form of fuel or biomass processing.06-06-2013
20130143296Delivery System for Cytotoxic Drugs by Bispecific Antibody Pretargeting - The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.06-06-2013
20130143297STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES - A hydrolytic enzyme is to be stabilized in a liquid surfactant preparation. This is achieved by using a component that stabilizes the hydrolytic enzyme and encompasses an aminophthalic acid.06-06-2013
20130143298STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES - A hydrolytic enzyme is to be stabilized in a liquid surfactant preparation. This is achieved by using a component that stabilizes the hydrolytic enzyme and encompasses a phthaloylglutamic acid and/or a phthaloylaspartic acid.06-06-2013
20130143299RNF8-FHA DOMAIN-MODIFIED PROTEIN AND METHOD OF PRODUCING THE SAME - Provided is an antigen-binding protein prepared merely by a method of in vitro selection using the RNF8-FHA domain, which has no intramolecular disulfide bond and functions in cells as it is. One to four loops extending from the FHA domain are randomized, and a recognition site for a target molecule is artificially created on the FHA domain surface to construct an RNF8-FHA domain library. Using the library, an antigen-binding protein is efficiently selected in vitro.06-06-2013
20120058536POLYMER MADE OF A PRIMARY AMINE FUNCTIONALIZED POLYMER AND A HEMICELLULOSE - The present invention relates to a polymer made of a primary amine functionalized polymer and a hemicellulose e.g. chitosan and xyloglucan, wherein the primary amine functionalized polymer is covalently bound to the hemicellulose, and to a cross-linking agent composition comprising the polymer. A method wherein manufacturing a cellulose containing product comprises the steps of; providing a cellulose containing product; treating said cellulose product with a cellulose adsorbing agent comprising a polymer made of a primary amine functionalized polymer and a hemicellulose e.g. chitosan and xyloglucan, and optionally other additives is also provided.03-08-2012
20080199934Functional peptide fiber, production method thereof and method for recovering peptide chains - This invention provides a functional peptide fiber which comprises a plurality of peptide structure units each containing at least one peptide chain, wherein peptide chains contained in each adjacent peptide structure units do not form peptide bond but are structured into a fibrous form by taking a β-sheet structure, and wherein at least one of the plurality of peptide structure units contains a peptide chain having a functional material connected thereto. Also disclosed are a method for producing the functional peptide fiber and a method for recovering peptide chains from the functional peptide fiber.08-21-2008
20110236951Biocomposite materials and methods for making the same - A particle (and a composition that includes a plurality of the particles) that includes at least one polypeptide molecule and at least one polymer covalently bound to the polypeptide molecule so as to form a polymer shell substantially encompassing the polypeptide molecule, wherein the particle does not define a dimension greater than about 1 μm. One example for making the particle includes modifying the polypeptide molecule to provide α, β-ethylenically unsaturated terminal functional groups, mixing the modified polypeptide molecule with a silicon-containing polymerizable compound, and subjecting the resulting mixture to conditions sufficient for polymerizing the polymerizable compound to form the particle.09-29-2011
20110275134Arrestin Biosensor - The present invention relates to a novel biosensor. A resonance energy transfter (RET) biosensor comprising a beta(β)-arrestin tagged with a first and a second chromophore, wherein said first chromophore is a fluorophore and said second chromophore is a fluorophore or a bioluminophore is described.11-10-2011
20120258514Kits for analysis of biological samples - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.10-11-2012
20100297726STABILIZED TRANSGLUTAMINASE AND PROCESS FOR PRODUCTION THEREOF - Disclosed is a transglutaminase having excellent stability. Also disclosed is a process for producing the transglutaminase. Specifically disclosed is a stabilized transglutaminase, which has such a structure in which a pro-sequence peptide of transglutaminase is bound to a mature transglutaminase. Also specifically disclosed is a process for producing stabilized transglutaminase, which includes the steps of: culturing a microorganism capable of producing transglutaminase under the conditions where transglutaminase can be produced; and separating and collecting matured transglutaminase having a pro-sequence peptide bound thereto from a culture medium.11-25-2010
20100297725Haptens, hapten conjugates, compositions thereof and method for their preparation and use - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.11-25-2010
20130157339STABILIZED PROTEASE COMPOSITION - A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula I:06-20-2013
20130157338RHAMM BINDING PEPTIDES - The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression.06-20-2013
20120282671MULTI-ARM POLYETHYLENE GLYCOL DERIVATIVES, CONJUGATES AND GELS OF PHARMACEUTICALS AND THE SAME - A multi-arm polyethylene glycol (I) having different kinds of reactive groups and the uses thereof are disclosed, which is formed by polymerizing ethylene oxide with oligo-pentaerythritol as an initiator, wherein, PEG is same or different and is —(CH2CH2O)m-, the average value of m is an integer of 2-250; I is an integer of 1 or more. The method for producing the multi-arm polyethylene glycol having different kinds of reactive groups, the multi-arm polyethylene glycol active derivatives comprising linking groups X attached to PEG and terminal reactive groups F attached to X, the gels formed by the multi-arm polyethylene glycol active derivatives, the drug conjugates formed by the multi-arm polyethylene glycol active derivatives and drug molecules, and the uses thereof in preparing drugs are also disclosed.11-08-2012
20120282670COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT - Provided herein are methods, nucleic acids, polypeptides, compositions, and kits relating to the conjugation of a heterologous polypeptide to a molecule of interest during production of the polypeptide in cell culture. In various embodiments, the heterologous polypeptide is linked to a sortase ligation sequence and the molecule of interest is linked to a complementary sortase ligation sequence, such that expression of the heterologous protein in the presence of the molecule of interest and cells expressing a surface-associated sortase with the sortase catalytic domain exposed to the extracellular medium results in ligation of the heterologous polypeptide to the molecule of interest to form a conjugated polypeptide.11-08-2012
20120282669Solubilized Phospholipids for Stabilizing Nucleic Acid Polymerases - Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule.11-08-2012
20130189756CHEMICALLY MODIFIED CARBONIC ANHYDRASES USEFUL IN CARBON CAPTURE SYSTEMS - The present disclosure relates to chemically modified carbonic anhydrase polypeptides and soluble compositions, homogenous liquid formulations comprising them. The chemically modified carbonic anhydrase polypeptides have improved properties relative to the same carbonic anhydrase polypeptide that is not chemically modified including the improved properties of increased activity and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides methods of preparing the chemically modified polypeptides and methods of using the chemically modified polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering.07-25-2013
20130189757AFFINITY PURIFICATION OF RNA UNDER NATIVE CONDITIONS BASED ON THE LAMBDA BOXB/N PEPTIDE INTERACTION - Reagents, methods, constructs and kits are described for immobilizing or purifying a target RNA of interest, based on the interaction of boxB RNA with a bacteriophage N peptide, which in turn is linked to an immobilizing moiety capable of binding to a solid support.07-25-2013
20120021487METHOD OF TREATING GAUCHER DISEASE - Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.01-26-2012
20120021486ENZYME-BASED NANOSCALE DECONTAMINATING COMPOSITES - The invention relates to decontaminating composites, and methods, compositions, and kits comprising the same. In some aspects, the invention relates to a decontaminating composite, comprising a perhydrolase associated with a carbon nanotube, that is useful for producing peracids.01-26-2012
20120021485HYBRID ALPHA-AMYLASES - Hybrid alpha-amylases are provided that share a conserved 3D structure in whole or in part with a wild-type Termamyl-like ?-amylase, e.g., a 01-26-2012
20120028332PROCESS FOR PRODUCTION OF AN ENZYME PRODUCT - The invention relates to a process for production of an enzyme product having a plurality of enzyme activities obtained by fermentation of an 02-02-2012
20130196406NOVEL PROTEIN-POLYMER NANOCAPSULES - Disclosed are protein nanocapsules, and in particular, nanocapsules that have high thermal stability and very high resistance to thermal inactivation when subjected to steam sterilization.08-01-2013
20130196407Non-Leachable Magnetic Cross-Linked Enzyme Aggregate - A non-leachable, crosslinked, on a nanometer scale formed magnetic enzyme aggregate, consisting of a non-layered, hybrid nano-composite of functionalised magnetic nanoparticles and aggregated enzyme particles, is described. The magnetic enzyme aggregate can have a high enzyme content, of up to 99%. The high enzyme content allows the use on a small scale, such as for example in a fluidised bed, of the magnetic enzyme aggregate. Also, a process for the preparation of the present magnetic enzyme aggregate is described.08-01-2013
20130203148MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITY AND ENHANCED TARGETING ACTIVITY - The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.08-08-2013
20100003736Polynucleotides encoding novel PCSK9 variants - The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.01-07-2010
20130095549TWEAK RECEPTOR - The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.04-18-2013
20120094357TAB MOLECULES - The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.04-19-2012
20120094356IN VIVO HALF LIFE INCREASED FUSION PROTEIN OR PEPTIDE MAINTAINED BY SUSTAINED IN VIVO RELEASE, AND METHOD FOR INCREASNG IN VIVO HALF-LIFE USING SAME - The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.04-19-2012
20130210113SMALL MOLECULE DYE CONJUGATES - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.08-15-2013
20130210115Method for Activating Catalyst Using Photothermal Nanomaterials - Disclosed is a method for activating a catalyst using the photothermal effects of photothermal nanomaterials, and more particularly to a method of activating a catalyst at a temperature, at which the catalyst has low or no activity, by irradiating a catalyst-photothermal nanomaterial composite with light. The method can activate the catalyst by increasing only the temperature around the nanomaterials without substantially changing the temperature of the reaction medium. A catalyst that generally has high activity at room temperature can be activated even at low temperature. Catalysts having high activity only under mild conditions are immobilized on photothermal nanomaterials so that they have activity even under low temperature and extreme conditions. The invention is useful when a catalyst substrate unstable at room temperature is used or a catalytic product unstable at room temperature is produced.08-15-2013
20130210116COMPOSITION AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.08-15-2013
20130210117CRYSTALS OF MEMBRANE PROTEINS - A polypeptide in crystalline form comprises a G-protein coupled receptor (GPCR) with an IC3 loop substituted by an amino acid residue sequence of lysozyme.08-15-2013
20130210114SYNTHETIC CHLOROPLAST TRANSIT PEPTIDES - This disclosure concerns compositions and methods for targeting peptides, polypeptides, and proteins to plastids of plastid-containing cells. In some embodiments, the disclosure concerns chloroplast transit peptides that may direct a polypeptide to a plastid, and nucleic acid molecules encoding the same. In some embodiments, the disclosure concerns methods for producing a transgenic plant material (e.g., a transgenic plant) comprising a chloroplast transit peptide, as well as plant materials produced by such methods, and plant commodity products produced therefrom.08-15-2013

Patent applications in class Stablizing an enzyme by forming a mixture, an adduct or a composition, or formation of an adduct or enzyme conjugate